AZN : Analysis & Opinions

  1. AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst ...

    December 19, 2014
    AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian ...
  2. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  3. Global Tensions and Fear - Ahead of Wall Street

    September 23, 2014
    The start of an expanded air campaign in the Iraq-Syria theater and weak data out of Europe provide the unsettling backdrop ...
  4. An Investing Legend Predicts A Major M&A Boom -- Here's How To ...

    August 7, 2014
    Some high-profile buyout deals have been falling apart lately. For instance, the third largest U.S. wireless carrier Sprint ...
  5. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  6. Global Markets Indicate Weakness - Ahead of Wall Street

    May 19, 2014
    Pre-open sentiment is pointing to a weak start for U.S. stocks, with soft overnight trading action across global markets.
  7. A Big Week for Economic & Earnings Data - Ahead of Wall Street

    April 28, 2014
    The week is packed with economic and Q1 earnings reports.
  8. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  9. Despite having the most to gain in the year ahead, British equities are still trading for cheap metrics when compared to the rest of Europe.

    The United Kingdom Is Ripe For Stock Pickers

    December 6, 2013
    With the situation in Europe finally moving ahead, investors may want to focus on the United Kingdom. Stocks within the nation ...
  10. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  11. Yet Another Failure Has Rigel Pharmaceuticals Almost Back To ...

    August 26, 2013
    Rigel sees yet another clinical failure from its pipeline.
  12. AstraZeneca Goes Back To The M&A Well Yet Again

    August 26, 2013
    AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade.
  13. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  14. Positive Phase III Data on Sanofi's U300 - Analyst Blog

    June 24, 2013
    Sanofi announced encouraging data from two phase III studies evaluating U300.
  15. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  16. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  17. AstraZeneca Looks To Fish Oil To Round Out Its Cardio Portfolio

    May 28, 2013
    AstraZeneca validates the purified fish oil concept, but not at an especially high price.
  18. Synergy Starts SP-333 Phase I Study - Analyst Blog

    January 29, 2013
    Synergy Pharmaceuticals Inc. (SGYP) recently initiated a phase Ib study on its inflammatory bowel disease (IBD) candidate, ...
  19. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  20. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  21. The Winners And Losers Of QE3

    November 15, 2012
    The market is a mix of winners and losers. When one side profits, the other side suffers.
  22. Blue Chip Stocks Paying The Highest Dividends

    October 25, 2012
    While picking individual stocks is risky, these blue chip companies have histories that show they can be good choices.
  23. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  24. Invest Like a Machine! - Investment Ideas

    September 21, 2012
    Last week, the Chicago Quantitative Alliance (CQA) held its annual fall conference. As a member, I was able to attend this ...
  25. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally. ...
  26. UK's Global Footprint Stocks

    June 27, 2012
    Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
  27. AstraZeneca Searches For Answers

    May 3, 2012
    AstraZeneca has an opportunity to do something big when it brings in a new CEO.
  28. The Costs Of Being Obese

    May 2, 2012
    Numbers released by the Mayo Clinic suggest obesity costs more than smoking.
  29. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  30. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  31. The War Against Alzheimer's Requires Thinking Small

    January 2, 2012
    A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure. ...
  32. The Contrarian Play In Europe

    October 26, 2011
    Nothing could be bolder than adding European stocks to a portfolio. Europe offers a fertile ground for contrarian investors. ...
  33. The Overlooked Dental Health Sector

    August 25, 2011
    While health care remains a great long-term portfolio position, many investors ignore the dental sub-sector. However, benefiting ...
  34. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  35. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  36. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  37. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  38. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma. ...
  39. The Future of Stem Cells

    June 15, 2010
    Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
  40. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  41. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount. ...
  42. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  43. An ETF To Play The U.K.

    January 13, 2010
    For investors who simply seek broad exposure to the overall U.K. economy, EWU may be your best bet.
  44. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others. ...
  45. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  46. 5 Stocks With Low P/Es And High Dividends

    June 19, 2009
    Finding undervalued gems can help boost porfolio returns. Check out five potential diamonds in the rough.
Trading Center